Cargando…
A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis
Understanding patient clinical progression is a key gateway to planning effective clinical trials and ultimately enabling bringing treatments to patients in need. In a rare disease like amyotrophic lateral sclerosis (ALS), studies of disease natural history critically depend on collaboration between...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606522/ https://www.ncbi.nlm.nih.gov/pubmed/34819914 http://dx.doi.org/10.3389/fneur.2021.770001 |
_version_ | 1784602349578223616 |
---|---|
author | Cook, Suzanne F. Rhodes, Thomas Schlusser, Courtney Han, Steve Chen, Chao Zach, Neta Murthy, Venkatesha Davé, Shreya |
author_facet | Cook, Suzanne F. Rhodes, Thomas Schlusser, Courtney Han, Steve Chen, Chao Zach, Neta Murthy, Venkatesha Davé, Shreya |
author_sort | Cook, Suzanne F. |
collection | PubMed |
description | Understanding patient clinical progression is a key gateway to planning effective clinical trials and ultimately enabling bringing treatments to patients in need. In a rare disease like amyotrophic lateral sclerosis (ALS), studies of disease natural history critically depend on collaboration between clinical centers, regions, and countries to enable creation of platforms to allow patients, caregivers, clinicians, and researchers to come together and more fully understand the condition. Rare disease registries and collaborative platforms such as those developed in ALS collect real-world data (RWD) in standardized formats, including clinical and biological specimen data used to evaluate risk factors and natural history of disease, treatment patterns and clinical (ClinROs) and patient- reported outcomes (PROs) and validate novel endpoints. Importantly, these data support the development of new therapeutics by supporting the evaluation of feasibility and design of clinical trials and offer valuable information on real-world disease trajectory and outcomes outside of the clinical trial setting for comparative purposes. RWD may help to accelerate therapy development by identifying and validating outcome measures and disease subpopulations. RWD can also make potential contributions to the evaluation of the safety and effectiveness of new indications for approved products and to satisfy post-approval regulatory and market access requirements. There is a lack of amalgamated information on available registries, databases, and other sources of real-world data on ALS; thus, a global review of all available resources was warranted. This targeted review identifies and describes ALS registries, biobanks and collaborative research networks that are collecting and synthesizing RWD for the purposes of increasing patient awareness and advancing scientific knowledge with the hope of expediting future development of new therapies. |
format | Online Article Text |
id | pubmed-8606522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86065222021-11-23 A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis Cook, Suzanne F. Rhodes, Thomas Schlusser, Courtney Han, Steve Chen, Chao Zach, Neta Murthy, Venkatesha Davé, Shreya Front Neurol Neurology Understanding patient clinical progression is a key gateway to planning effective clinical trials and ultimately enabling bringing treatments to patients in need. In a rare disease like amyotrophic lateral sclerosis (ALS), studies of disease natural history critically depend on collaboration between clinical centers, regions, and countries to enable creation of platforms to allow patients, caregivers, clinicians, and researchers to come together and more fully understand the condition. Rare disease registries and collaborative platforms such as those developed in ALS collect real-world data (RWD) in standardized formats, including clinical and biological specimen data used to evaluate risk factors and natural history of disease, treatment patterns and clinical (ClinROs) and patient- reported outcomes (PROs) and validate novel endpoints. Importantly, these data support the development of new therapeutics by supporting the evaluation of feasibility and design of clinical trials and offer valuable information on real-world disease trajectory and outcomes outside of the clinical trial setting for comparative purposes. RWD may help to accelerate therapy development by identifying and validating outcome measures and disease subpopulations. RWD can also make potential contributions to the evaluation of the safety and effectiveness of new indications for approved products and to satisfy post-approval regulatory and market access requirements. There is a lack of amalgamated information on available registries, databases, and other sources of real-world data on ALS; thus, a global review of all available resources was warranted. This targeted review identifies and describes ALS registries, biobanks and collaborative research networks that are collecting and synthesizing RWD for the purposes of increasing patient awareness and advancing scientific knowledge with the hope of expediting future development of new therapies. Frontiers Media S.A. 2021-11-08 /pmc/articles/PMC8606522/ /pubmed/34819914 http://dx.doi.org/10.3389/fneur.2021.770001 Text en Copyright © 2021 Cook, Rhodes, Schlusser, Han, Chen, Zach, Murthy and Davé. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Cook, Suzanne F. Rhodes, Thomas Schlusser, Courtney Han, Steve Chen, Chao Zach, Neta Murthy, Venkatesha Davé, Shreya A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis |
title | A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis |
title_full | A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis |
title_fullStr | A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis |
title_full_unstemmed | A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis |
title_short | A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis |
title_sort | descriptive review of global real world evidence efforts to advance drug discovery and clinical development in amyotrophic lateral sclerosis |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606522/ https://www.ncbi.nlm.nih.gov/pubmed/34819914 http://dx.doi.org/10.3389/fneur.2021.770001 |
work_keys_str_mv | AT cooksuzannef adescriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT rhodesthomas adescriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT schlussercourtney adescriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT hansteve adescriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT chenchao adescriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT zachneta adescriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT murthyvenkatesha adescriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT daveshreya adescriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT cooksuzannef descriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT rhodesthomas descriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT schlussercourtney descriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT hansteve descriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT chenchao descriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT zachneta descriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT murthyvenkatesha descriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis AT daveshreya descriptivereviewofglobalrealworldevidenceeffortstoadvancedrugdiscoveryandclinicaldevelopmentinamyotrophiclateralsclerosis |